MTAP and neoplasm: Following a study to determine the maximum tolerateddose (MTD) in BALB/c nude mice, oral administration of TNG908 at well-tolerateddoses (30 or 120 mg/kg BID) in the LU99 MTAP-null NSCLC CDX modelresulted in strong, dose-dependent antitumor activity including a48% tumor regression at the 120 mg/kg BID dose level (Figure 11).